What can we learn from PROFILE and FIRST?
Over the last 20 years a single principle has guided the development of new drugs for chronic heart failure - they need to produce favourable haemodynamic effects either by enhancing cardiac contractility or by reducing wall stress. Two drugs showing such promise were flosequinan and epoprostenol. However, following favourable results in short-term trials, long-term trials for both drugs had to be terminated prematurely, within 6 weeks of each other, due to unacceptably high mortality in the treatment groups. Why did this happen? The results of both trials and the lessons that can be learnt from them were discussed at the American College of Cardiology 43rd Annual Scientific Session, held in Atlanta, Georgia, US, March 13-17th.
KeywordsChronic Heart Failure Haemodynamic Effect Cardiac Contractility Epoprostenol Neurohormonal Activation
Unable to display preview. Download preview PDF.